Linkedin Facebook Contact with Pharma Industrial India
 

Last edition

July-August, 2026
All magazines
Subscribe to our magazine
autodoc
 
Home › News › Quality / GMP

Cipla's InvaGen Facility Gets Zero US FDA Form 483 Observations

Cipla's InvaGen Facility Gets Zero US FDA Form 483 Observations

Cipla recently announced that the US Food and Drug Administration (FDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals, in Hauppauge, Long Island, New York, USA.

The inspection was conducted from October 19 to October 22, 2026.

It concluded with zero Form 483 observations, according to the company.
Read more on:
Cipla InvaGen US FDA Inspection Cipla Zero Form 483 Observations Current Good Manufacturing Practice (cGMP) InvaGen Pharmaceuticals InvaGen Pharmaceuticals US FDA Inspection US FDA cGMP Inspection
More news about: quality / gmp | Published by News Bureau | October - 27 - 2026

Last news about this category

Alembic Pharma Gets US FDA Final Approval for Otic Suspension Alembic Pharma Gets US FDA Final Approval for Otic Suspension
Cognition Therapeutics Secures US Patent for Zervimesine Cognition Therapeutics Secures US Patent for Zervimesine
Vir Biotechnology's VIR-5500 Receives FDA Fast Track Designation for Prostate Cancer Vir Biotechnology's VIR-5500 Receives FDA Fast Track Designation for Prostate Cancer
Alvotech Gets FDA Approval for Second AVT02 Manufacturing Suite Alvotech Gets FDA Approval for Second AVT02 Manufacturing Suite
US FDA Inspection of Unichem's Goa Facility Ends With 5 Observations US FDA Inspection of Unichem's Goa Facility Ends With 5 Observations
Envoy Medical Expands Global IP Portfolio to 97 Patents Envoy Medical Expands Global IP Portfolio to 97 Patents
FDA Updates Winrevair Label With Phase 3 HYPERION Data FDA Updates Winrevair Label With Phase 3 HYPERION Data
Anixa Biosciences Secures Australian Patent for Breast Cancer Vaccine Anixa Biosciences Secures Australian Patent for Breast Cancer Vaccine
FDA Grants Priority Review to Insmed's Arikayce sNDA FDA Grants Priority Review to Insmed's Arikayce sNDA
Japan Approves Merck's Keytruda Qlex for Subcutaneous Use Japan Approves Merck's Keytruda Qlex for Subcutaneous Use
 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members

Privacy Policy | Cookies Policy